Kybella Deoxycholic Acid 20mg/2ml

Kybella® is a prescription injectable medication containing deoxycholic acid, developed by Allergan (AbbVie, USA). It is an FDA-approved injectable treatment for submental fat reduction (double chin fat). It is intended only for administration by trained and licensed healthcare professionals, typically in medical aesthetics or dermatology settings. Kybella is a synthetic form of deoxycholic acid, a naturally occurring bile acid in the human body that helps break down dietary fat. It is not a filler, not a skin booster, and not a mesotherapy cocktail —it is a fat-dissolving (adipolytic) drug.

Packaging

• 1 vial = 2 mL solution (20 mg total, 10 mg/mL concentration)
• Single-use vial
• Sterile injectable pharmaceutical product
• Prescription-only medicine

Composition

Each 2 mL vial contains:

• Deoxycholic acid: 10 mg/mL (total 20 mg per vial)
• Buffering agents (to maintain physiological pH)
• Sodium hydroxide and hydrochloric acid (for pH adjustment)
• Water for injection

Safety Information

Must only be administered by trained healthcare professionals.

Common side effects:

• Swelling (very common and expected)
• Bruising
• Pain or burning sensation
• Numbness or firmness under skin

Less common risks:

• Nerve injury (temporary facial weakness)
• Irregular contour or nodules
• Infection
• Excessive fat loss or asymmetry

Contraindications:

• Infection at injection site
• Difficulty swallowing or neck abnormalities
• Pregnancy or breastfeeding (generally avoided)

Mechanism of Action

Kybella works by chemically disrupting fat cell membranes:

• Deoxycholic acid acts as a detergent-like molecule
• It breaks down adipocyte (fat cell) membranes
• Released fat is naturally cleared by the body’s lymphatic system
• Once destroyed, fat cells do not regenerate in the treated area

Overall effect:

• Permanent reduction of localized fat deposits in treated areas

Product Features

• Synthetic deoxycholic acid formulation
• FDA-approved for double chin reduction
• Permanent fat cell destruction in treated area
• Non-surgical alternative to liposuction for small fat deposits
• Precision injectable treatment

Expected Results

Typical outcomes include:

• Gradual reduction of submental fat
• Improved chin and jawline definition
• More sculpted lower face contour

Timeline:

• Results develop gradually over multiple sessions (weeks between treatments)
• Full results typically visible after 2–4 months or more, depending on protocol

Advantages

• Permanent fat reduction in treated area
• Non-surgical procedure
• Targeted contour improvement
• No need for anesthesia or surgery
• Predictable localized fat reduction

Common Treatment Areas

Approved and commonly used for:

• Submental fat (under the chin)

Off-label (only under medical supervision in some regions):

• Small localized fat pockets in body contouring (varies by regulation)